Cargando…
Interleukin-1 Receptor Modulation Using β-Substituted α-Amino-γ-Lactam Peptides From Solid-Phase Synthesis and Diversification
As a key cytokine mediator of inflammation, interleukin-1β (IL-1β) binds to the IL-1 receptor (IL-1R) and activates various downstream signaling mediators, including NF-κB, which is required for immune vigilance and cellular protection. Toward the development of IL-1-targeting therapeutics which exh...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783595/ https://www.ncbi.nlm.nih.gov/pubmed/33415098 http://dx.doi.org/10.3389/fchem.2020.610431 |
_version_ | 1783632143328477184 |
---|---|
author | Geranurimi, Azade Cheng, Colin W. H. Quiniou, Christiane Côté, France Hou, Xin Lahaie, Isabelle Boudreault, Amarilys Chemtob, Sylvain Lubell, William D. |
author_facet | Geranurimi, Azade Cheng, Colin W. H. Quiniou, Christiane Côté, France Hou, Xin Lahaie, Isabelle Boudreault, Amarilys Chemtob, Sylvain Lubell, William D. |
author_sort | Geranurimi, Azade |
collection | PubMed |
description | As a key cytokine mediator of inflammation, interleukin-1β (IL-1β) binds to the IL-1 receptor (IL-1R) and activates various downstream signaling mediators, including NF-κB, which is required for immune vigilance and cellular protection. Toward the development of IL-1-targeting therapeutics which exhibit functional selectivity, the all-D-amino acid peptide 1 (101.10, H-D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH(2)) was conceived as an allosteric IL-1R modulator that conserves NF-κB signaling while inhibiting other IL-1-activated pathways. Employing β-hydroxy-α-amino-γ-lactam (Hgl) stereoisomers to study the conformation about the Thr(3) residue in 1, [(3R,4S)-Hgl(3)]-1 (2b), among all possible diastereomers, was found to exhibit identical in vitro and in vivo activity as the parent peptide and superior activity to the α-amino-γ-lactam (Agl) counterpart. Noting the relevance of the β-hydroxyl substituent and configuration for the activity of (3R,4S)-2b, fifteen different β-substituted-Agl(3) analogs of 1 (e.g., 2c-q) have now been synthesized by a combination of solution- and solid-phase methods employing N-Fmoc-β-substituted-Agl(3)-Val-OH dipeptide building blocks. Introduction of a β-azido-Agl(3) residue into the resin bound peptide and subsequent reduction and CuAAC chemistry gave access to a series of amine and triazole derivatives (e.g., 2h-q). β-Substituted-[Agl(3)]-1 analogs 2c-q exhibited generally similar circular dichroism (CD) spectra as that of Hgl analog 2b in water, presenting curve shapes indicative of β-turn structures. The relevance of the β-substituent was indicated in rodent models of preterm labor and retinopathy of prematurity (ROP), in which certain analogs inhibited preterm birth and vaso-obliteration, respectively, with activity similar to 1 and 2b. The β-substituted-[Agl(3)]-1 analogs exhibited functional selectivity on IL-1-induced signaling pathways. The described solid-phase method has provided discerning probes for exploring peptide structure-activity relationships and valuable leads for developing prototypes to treat inflammatory events leading to prematurity and retinopathy of prematurity, which are leading causes of infant morbidity and blindness respectively. |
format | Online Article Text |
id | pubmed-7783595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77835952021-01-06 Interleukin-1 Receptor Modulation Using β-Substituted α-Amino-γ-Lactam Peptides From Solid-Phase Synthesis and Diversification Geranurimi, Azade Cheng, Colin W. H. Quiniou, Christiane Côté, France Hou, Xin Lahaie, Isabelle Boudreault, Amarilys Chemtob, Sylvain Lubell, William D. Front Chem Chemistry As a key cytokine mediator of inflammation, interleukin-1β (IL-1β) binds to the IL-1 receptor (IL-1R) and activates various downstream signaling mediators, including NF-κB, which is required for immune vigilance and cellular protection. Toward the development of IL-1-targeting therapeutics which exhibit functional selectivity, the all-D-amino acid peptide 1 (101.10, H-D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH(2)) was conceived as an allosteric IL-1R modulator that conserves NF-κB signaling while inhibiting other IL-1-activated pathways. Employing β-hydroxy-α-amino-γ-lactam (Hgl) stereoisomers to study the conformation about the Thr(3) residue in 1, [(3R,4S)-Hgl(3)]-1 (2b), among all possible diastereomers, was found to exhibit identical in vitro and in vivo activity as the parent peptide and superior activity to the α-amino-γ-lactam (Agl) counterpart. Noting the relevance of the β-hydroxyl substituent and configuration for the activity of (3R,4S)-2b, fifteen different β-substituted-Agl(3) analogs of 1 (e.g., 2c-q) have now been synthesized by a combination of solution- and solid-phase methods employing N-Fmoc-β-substituted-Agl(3)-Val-OH dipeptide building blocks. Introduction of a β-azido-Agl(3) residue into the resin bound peptide and subsequent reduction and CuAAC chemistry gave access to a series of amine and triazole derivatives (e.g., 2h-q). β-Substituted-[Agl(3)]-1 analogs 2c-q exhibited generally similar circular dichroism (CD) spectra as that of Hgl analog 2b in water, presenting curve shapes indicative of β-turn structures. The relevance of the β-substituent was indicated in rodent models of preterm labor and retinopathy of prematurity (ROP), in which certain analogs inhibited preterm birth and vaso-obliteration, respectively, with activity similar to 1 and 2b. The β-substituted-[Agl(3)]-1 analogs exhibited functional selectivity on IL-1-induced signaling pathways. The described solid-phase method has provided discerning probes for exploring peptide structure-activity relationships and valuable leads for developing prototypes to treat inflammatory events leading to prematurity and retinopathy of prematurity, which are leading causes of infant morbidity and blindness respectively. Frontiers Media S.A. 2020-12-21 /pmc/articles/PMC7783595/ /pubmed/33415098 http://dx.doi.org/10.3389/fchem.2020.610431 Text en Copyright © 2020 Geranurimi, Cheng, Quiniou, Côté, Hou, Lahaie, Boudreault, Chemtob and Lubell. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Chemistry Geranurimi, Azade Cheng, Colin W. H. Quiniou, Christiane Côté, France Hou, Xin Lahaie, Isabelle Boudreault, Amarilys Chemtob, Sylvain Lubell, William D. Interleukin-1 Receptor Modulation Using β-Substituted α-Amino-γ-Lactam Peptides From Solid-Phase Synthesis and Diversification |
title | Interleukin-1 Receptor Modulation Using β-Substituted α-Amino-γ-Lactam Peptides From Solid-Phase Synthesis and Diversification |
title_full | Interleukin-1 Receptor Modulation Using β-Substituted α-Amino-γ-Lactam Peptides From Solid-Phase Synthesis and Diversification |
title_fullStr | Interleukin-1 Receptor Modulation Using β-Substituted α-Amino-γ-Lactam Peptides From Solid-Phase Synthesis and Diversification |
title_full_unstemmed | Interleukin-1 Receptor Modulation Using β-Substituted α-Amino-γ-Lactam Peptides From Solid-Phase Synthesis and Diversification |
title_short | Interleukin-1 Receptor Modulation Using β-Substituted α-Amino-γ-Lactam Peptides From Solid-Phase Synthesis and Diversification |
title_sort | interleukin-1 receptor modulation using β-substituted α-amino-γ-lactam peptides from solid-phase synthesis and diversification |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783595/ https://www.ncbi.nlm.nih.gov/pubmed/33415098 http://dx.doi.org/10.3389/fchem.2020.610431 |
work_keys_str_mv | AT geranurimiazade interleukin1receptormodulationusingbsubstitutedaaminoglactampeptidesfromsolidphasesynthesisanddiversification AT chengcolinwh interleukin1receptormodulationusingbsubstitutedaaminoglactampeptidesfromsolidphasesynthesisanddiversification AT quiniouchristiane interleukin1receptormodulationusingbsubstitutedaaminoglactampeptidesfromsolidphasesynthesisanddiversification AT cotefrance interleukin1receptormodulationusingbsubstitutedaaminoglactampeptidesfromsolidphasesynthesisanddiversification AT houxin interleukin1receptormodulationusingbsubstitutedaaminoglactampeptidesfromsolidphasesynthesisanddiversification AT lahaieisabelle interleukin1receptormodulationusingbsubstitutedaaminoglactampeptidesfromsolidphasesynthesisanddiversification AT boudreaultamarilys interleukin1receptormodulationusingbsubstitutedaaminoglactampeptidesfromsolidphasesynthesisanddiversification AT chemtobsylvain interleukin1receptormodulationusingbsubstitutedaaminoglactampeptidesfromsolidphasesynthesisanddiversification AT lubellwilliamd interleukin1receptormodulationusingbsubstitutedaaminoglactampeptidesfromsolidphasesynthesisanddiversification |